<DOC>
	<DOCNO>NCT01093105</DOCNO>
	<brief_summary>The objective study evaluate natural history disease progression infant globoid cell leukodystrophy ( GLD ) .</brief_summary>
	<brief_title>An Observational Study Pediatric Subjects With Globoid Cell Leukodystrophy ( GLD )</brief_title>
	<detailed_description>This study conduct gather prospective data disease progression infant diagnose GLD . This study perform use protocol-defined , standardized assessment include clinical , developmental , neurologic measure . All study visit conduct subject 's home . No travel study site necessary .</detailed_description>
	<mesh_term>Leukodystrophy , Globoid Cell</mesh_term>
	<criteria>Subjects must meet follow criterion consider eligible study : 1 . The subject document diagnosis GLD evidence GALC enzyme activity GALC genotype predictive GLD . 2 . The subject must clinical sign symptoms consistent diagnosis infantile GLD include least 2 follow : 1 . Chronic difficulty feed unexplained irritability `` fisting '' sign abnormal increase tone 2 . CT MRI imaging , perform diagnostic evaluation prior enrollment , consistent GLD 3 . Failure meet least 2 agespecific developmental milestone consistent GLD 4 . Loss deep tendon reflex abnormal visual fixation optic atrophy 3 . The subject document onset sign symptom consistent GLD &lt; 12 month age &lt; 21 month age time study entry . 4 . The subject born gestational age 3541 week . 5 . The subject birth weight â‰¥2 kg . 6 . At study entry , subject must able maintain oral nutrition hydration without use supportive measure , define use feed tube . 7 . At study entry , subject must able maintain ventilation without use invasive supportive measure , define use breathe tube . 8 . The subject must able , opinion Investigator , accommodate protocol requirement , include feasibility study visit . 9 . The subject 's parent ( ) legal guardian must voluntarily sign Institutional Review Board/Independent Ethics Committeeapproved inform consent form relevant aspect study explain discuss subject 's parent ( ) , legal guardian . Subjects meet follow criterion eligible study : 1 . The subject neurologic , hear vision impairment , difficulty swallow feeding , respiratory complication , behavioral disturbance , medical condition due GLD likely confound scientific integrity interpretation study assessment , determine Investigator . 2 . The subject receive treatment investigational drug device within 30 day prior study enrollment study completion . 3 . The subject receive cord blood bone marrow transplant plan receive one study . 4 . The subject 's parent ( ) legal guardian unable understand nature , scope , possible consequence study , agree comply protocol define schedule assessment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Months</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Leukodystrophy , Globoid Cell</keyword>
	<keyword>Classic Globoid Cell Leukodystrophy</keyword>
	<keyword>Early-Onset Globoid Cell Leukodystrophy</keyword>
	<keyword>Globoid Cell Leukodystrophy</keyword>
	<keyword>Globoid Cell Leukoencephalopathy</keyword>
	<keyword>Infantile Globoid Cell Leukodystrophy</keyword>
	<keyword>Late-Onset Globoid Cell Leukodystrophy</keyword>
	<keyword>Leukodystrophy , Globoid Cell , Classic</keyword>
	<keyword>Leukodystrophy , Globoid Cell , Early-Onset</keyword>
	<keyword>Leukodystrophy , Globoid Cell , Infantile</keyword>
	<keyword>Leukodystrophy , Globoid Cell , Late-Onset</keyword>
	<keyword>Psychosine</keyword>
	<keyword>galactosylsphingosine ( psychosine ) beta-galactosidase</keyword>
	<keyword>Psychosine-UDP galactosyltransferase</keyword>
	<keyword>Krabbe Disease</keyword>
	<keyword>Krabbe Leukodystrophy</keyword>
	<keyword>Krabbe 's Disease</keyword>
	<keyword>Krabbe 's Leukodystrophy</keyword>
</DOC>